Intraocular dynamics of vascular endothelial growth factor levels in patients with neovascular glaucoma

Intraocular dynamics of vascular endothelial growth factor levels in patients with neovascular glaucoma - Aqueous humor VEGF levels before and after intravitreal bevacizumab for neovascular glaucoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003646

Enrollment

Registered

2010-05-24

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular glaucoma

Interventions

intravitreal injection of 1.0-mg bevacizumab intravitreal injection of 0.1-mg bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eyes with neovascular glaucoma scheduled for intravitreal injection of bevacizumab

Exclusion criteria

Exclusion criteria: Eyes with a past history of intravitreal pharmacotherapy

Design outcomes

Primary

Measure	Time frame
Changes of aqueous humor VEGF concentrations and intraocular pressures beore and after the high- and low-doses of intravitreal bevacizumab	—

Secondary

Measure	Time frame
Clinical evaluation of the changes in iris and angle neovascularization before and after the high- and low-doses of intravitreal bevacizumab	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026